MedTrace Logo

PSOREAL - Managing PSOriasis in the REAL World

NCT02935582 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1214

Last updated 2021-06-14

No results posted yet for this study

Summary

Multinational real-life study of current psoriasis treatment strategies, topical treatment patterns and treatment outcomes of these treatments, including the newly introduced calcipotriol/betamethasone dipropionate aerosol foam fixed combination product Enstilar® (calcipotriol/betamethasone dipropionate).

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

Enstilar® aerosol foam

Treatment according to local labelling

DRUG

Other topical

Treatment according to local practise

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Kreesten M Madsen, MD, PhD · LEO Pharma

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2020-12-30
Completion
2020-12-30

Countries

  • Canada
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02935582 on ClinicalTrials.gov